Facebook-f Twitter Tiktok Instagram Youtube
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
CLRB — Price & Forward EBITDA
Forward EBITDA (M)

Float Short %

1.15

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

-0.52

EPS Last/This Y

4.16

EPS This/Next Y

1.1

Price

2.72

Target Price

12

Analyst Recom

1

Performance Q

-2.17

Upside

-13,503.7%

Beta

0.35

Ticker: CLRB



20 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-02-27CLRB3.26N/AN/A0
2026-03-02CLRB3.01N/AN/A0
2026-03-03CLRB2.7711N/AN/A0
2026-03-04CLRB2.86N/AN/A0
2026-03-05CLRB2.76N/AN/A0
2026-03-06CLRB2.75N/AN/A0
2026-03-09CLRB2.72N/AN/A0
2026-03-10CLRB3.05N/AN/A0
2026-03-11CLRB2.95N/AN/A0
2026-03-12CLRB3.27N/AN/A0
2026-03-13CLRB3.23N/AN/A0
2026-03-17CLRB3.34N/AN/A0
2026-03-18CLRB3.2N/AN/A0
2026-03-19CLRB3.18N/AN/A0
2026-03-20CLRB3.21N/AN/A0
2026-03-23CLRB3.1N/AN/A0
2026-03-24CLRB3.05N/AN/A0
2026-03-25CLRB2.98N/AN/A0
2026-03-26CLRB2.91N/AN/A0
2026-03-27CLRB2.72N/AN/A0
DateSymbolLatestP/C OIP/C VolTotal OI
20 items Current Page1 of 1



20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-02-27CLRB3.25-306.7- -8.92
2026-03-02CLRB3.03-306.7- -8.92
2026-03-03CLRB2.70-306.7- -8.92
2026-03-04CLRB2.90-306.7- -8.92
2026-03-05CLRB2.75-306.7- -8.92
2026-03-06CLRB2.78-306.7- -8.92
2026-03-09CLRB2.8172.7- -4.15
2026-03-10CLRB3.0972.7- -4.15
2026-03-11CLRB2.9472.7- -4.15
2026-03-12CLRB3.2072.7- -4.15
2026-03-13CLRB3.2567.9- -5.54
2026-03-17CLRB3.3455.1- -4.20
2026-03-18CLRB3.2155.1- -4.20
2026-03-19CLRB3.1655.1- -4.20
2026-03-20CLRB3.1455.1- -4.20
2026-03-23CLRB3.1155.1- -4.20
2026-03-24CLRB3.0555.1- -4.20
2026-03-25CLRB2.9955.1- -4.20
2026-03-26CLRB2.9755.1- -4.20
2026-03-27CLRB2.7255.1- -4.20
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1



20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-02-27CLRB-0.086.732.94
2026-03-02CLRB-0.086.762.94
2026-03-03CLRB-0.086.762.94
2026-03-04CLRB-0.086.762.94
2026-03-05CLRB-0.086.762.94
2026-03-06CLRB-0.086.762.94
2026-03-09CLRB-0.086.712.94
2026-03-10CLRB-0.086.712.94
2026-03-11CLRB-0.086.712.26
2026-03-12CLRB-0.086.712.26
2026-03-13CLRB-0.086.712.26
2026-03-17CLRB-0.086.712.26
2026-03-18CLRB-0.086.712.26
2026-03-19CLRB-0.086.712.26
2026-03-20CLRB-0.086.712.26
2026-03-23CLRB-0.086.712.26
2026-03-24CLRB-0.086.712.26
2026-03-25CLRB-0.086.711.15
2026-03-26CLRB-0.086.711.15
2026-03-27CLRB-0.086.711.15
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS​

-0.53

Avg. EPS Est. Current Quarter

-1.89

Avg. EPS Est. Next Quarter

-1.05

Insider Transactions

-0.08

Institutional Transactions

6.71

Beta

0.35

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

4

Growth Score

19

Sentiment Score

2

Actual DrawDown %

99.5

Max Drawdown 5-Year %

-99.5

Target Price

12

P/E

Forward P/E

PEG

P/S

P/B

1.43

P/Free Cash Flow

EPS

-10.34

Average EPS Est. Cur. Y​

-4.2

EPS Next Y. (Est.)

-3.1

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.46

Return on Equity vs Sector %

-282.6

Return on Equity vs Industry %

-266.3

EPS 1 7Days Diff

4

EPS 1 30Days Diff

3.32

EBIT Estimation

◆ CLRB Healthcare
$2.70
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
20/20
Pullback
15/25
Volume
11/15
Valuation
12/20
TP/AR
2/10
Options
0/10
RSI
37
Range 1M
10.4%
🚀
Momentum Growth
Ride accelerating trends
N/A
37 /100
WEAK
Momentum
9/25
Growth
23/30
Estimates
0/20
Inst/Vol
5/15
Options
0/10
EPS Yr
52.3%
EPS NY
23.5%
52W%
1.5%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +344.4% upside
Quality
2/30
Valuation
16/30
Growth
19/25
Stability
7/10
LT Trend
4/5
Upside
+344.4%
Quality
4
Click a card to see score breakdown Full Analysis →
Cellectar Biosciences, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 11
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR125, an iodine-125 Auger-emitting radioconjugate program; and CLR 225, an actinium-225 based program. The company has collaborative with Orano Med to develop alpha emitter lead-212 conjugated to phospholipid ether series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.
CLRB

Latest News

—
Caricamento notizie per CLRB…
stock quote shares CLRB – Cellectar Biosciences Inc. Stock Price stock today
news today CLRB – Cellectar Biosciences Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch CLRB – Cellectar Biosciences Inc. yahoo finance google finance
stock history CLRB – Cellectar Biosciences Inc. invest stock market
stock prices CLRB premarket after hours
ticker CLRB fair value insiders trading